SynthesisClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2020
Review of trials currently testing treatment and prevention of COVID-19.
Synthesis in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 56 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 3 syntheses or guidelines pooled it, 106 citations in OpenAlex.
- Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials.The Lancet. Respiratory medicine · 2023Pooled it
- Evaluating the methodology of studies conducted during the global COVID-19 pandemic: A systematic review of randomized controlled trials.Journal of integrative medicine · 2021Pooled it
- Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2021Pooled it
- Early mortality benefit with COVID-19 convalescent plasma: a matched control study.British journal of haematology · 2021Trial
- Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia.Frontiers in immunology · 2021Trial
- Computerized monitoring of COVID-19 trials, studies and registries in ClinicalTrials.gov registry.PeerJ · 2020Trial
- Assessing the Impact of Colchicine on Pulmonary Fibrosis Using Imaging in Patients With Moderate-to-Severe COVID-19 Pneumonia.Canadian respiratory journal · 2026Article
- COVID-19 associated acute kidney injury.Infectious diseases & immunity · 2025Review
- Review
- Disparities in COVID-19 clinical studies from high-income and low-and middle-income countries.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023Article
- Platform trials as the way forward in infectious disease' clinical research: the case of coronavirus disease 2019.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2023Article
- Evaluation of Global Post-Outbreak COVID-19 Treatment Interventions: A Systematic Review and Bibliometric Analysis of Randomized Controlled Trials.Journal of multidisciplinary healthcare · 2023Review
- Profiles of host immune impairment inHeliyon · 2022Review
- Future Perspectives in the Diagnosis and Treatment of Sepsis and Septic Shock.Medicina (Kaunas, Lithuania) · 2022Article
- A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines.AAPS PharmSciTech · 2022Review
- Outcomes assessed in therapeutic randomized controlled trials in hospitalized patients with COVID-19: is the meta Core Outcome Set (meta-COS) adopted?Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022Article
- Executable network of SARS-CoV-2-host interaction predicts drug combination treatments.NPJ digital medicine · 2022Article
- Article
- High doses of favipiravir in two men survivors of Ebola virus disease carrying Ebola virus in semen in Guinea.IDCases · 2022Article
- Reinforcing the supply chain of umifenovir and other antiviral drugs with retrosynthetic software.Nature communications · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs COVID-19 cases continue to rise globally, evidence from large randomized controlled trials is still lacking. Currently, numerous trials testing potential treatment and preventative options are being undertaken all over the world.
objectivesWe summarized all registered clinical trials examining treatment and prevention options for COVID-19. Additionally, we evaluated the quality of the retrieved studies. DATA SOURCES: Clinicaltrials.gov, the Chinese Clinical Trial Registry and the European Union Clinical Trials Register were systematically searched. STUDY ELIGIBILITY CRITERIA: Registered clinical trials examining treatment and/or prevention options for COVID-19 were included. No language, country or study design restrictions were applied. We excluded withdrawn or cancelled studies and trials not reporting therapeutic or preventative strategies for COVID-19. PARTICIPANTS AND
interventionsNo restrictions in terms of participants' age and medical background or type of intervention were enforced.
methodsThe registries were searched using the term 'coronavirus' or 'COVID-19' from their inception until 26 March 2020. Additional manual search of the registries was also performed. Eligible studies were summarized and tabulated. Interventional trials were methodologically analysed, excluding expanded access studies and trials testing traditional Chinese medicine.
resultsIn total, 309 trials evaluating therapeutic management options, 23 studies assessing preventive strategies and three studies examining both were retrieved. Finally, 214 studies were methodologically reviewed. Interventional treatment studies were mostly randomized (n = 150/198, 76%) and open label (n = 73/198, 37%) with a median number of planned inclusions of 90 (interquartile range 40-200). Major categories of interventions that are currently being investigated are discussed.
conclusionsNumerous clinical trials have been registered since the onset of the COVID-19 pandemic. Summarized data on these trials will assist physicians and researchers to promote patient care and guide future research efforts for COVID-19 pandemic containment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.